In the second-largest payment ever by a drug company, Abbott Laboratories agreed Monday to pay $1.5 billion and enter a guilty plea in federal district court in Virginia for unlawfully marketing one of its medications to seniors for off-label uses.
The settlement, announced in a Justice Department statement today, is still pending approval by the court. The settlement provides for a criminal fine and forfeiture of $700 million, and civil settlements of $800 million, to be split between the federal government and states that choose to participate in the agreement.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]